Cargando…
Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes
Interactions between anti-hypertensive agents (ACEI), comorbidities, inflammation, and stress status may impact hospital stay duration in COVID-19 patients. This retrospective study analyzed epidemiological data, comorbidities, metabolic/inflammatory markers, and clinical information from 165 SARS-C...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769875/ https://www.ncbi.nlm.nih.gov/pubmed/35065299 http://dx.doi.org/10.1016/j.vph.2022.106955 |
_version_ | 1784635241263005696 |
---|---|
author | Martínez-Urbistondo, Maria Moreno-Torres, Víctor Mora-Vargas, Alberto Expósito-Palomo, Esther Castejón-Díaz, Raquel Daimiel, Lidia Ramos-Lopez, Omar San-Cristóbal, Rodrigo Vargas, Juan A. Martínez, J. Alfredo |
author_facet | Martínez-Urbistondo, Maria Moreno-Torres, Víctor Mora-Vargas, Alberto Expósito-Palomo, Esther Castejón-Díaz, Raquel Daimiel, Lidia Ramos-Lopez, Omar San-Cristóbal, Rodrigo Vargas, Juan A. Martínez, J. Alfredo |
author_sort | Martínez-Urbistondo, Maria |
collection | PubMed |
description | Interactions between anti-hypertensive agents (ACEI), comorbidities, inflammation, and stress status may impact hospital stay duration in COVID-19 patients. This retrospective study analyzed epidemiological data, comorbidities, metabolic/inflammatory markers, and clinical information from 165 SARS-CoV-2 positive patients. In a multiple linear regression model, an IL-6 higher than 100 mg/L, glucose at admission (baseline levels at the hospital entry), and the interaction between ACEI administration and LDH predicted the days of hospital admission (P < 0.001). In conclusion, hypertensive patients suffering more severe inflammatory condition assessed by LDH levels clinically benefited more and reduced the hospital stay when prescribed ACEI agents than those with lower systemic baseline inflammation at admission. |
format | Online Article Text |
id | pubmed-8769875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87698752022-01-20 Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes Martínez-Urbistondo, Maria Moreno-Torres, Víctor Mora-Vargas, Alberto Expósito-Palomo, Esther Castejón-Díaz, Raquel Daimiel, Lidia Ramos-Lopez, Omar San-Cristóbal, Rodrigo Vargas, Juan A. Martínez, J. Alfredo Vascul Pharmacol Article Interactions between anti-hypertensive agents (ACEI), comorbidities, inflammation, and stress status may impact hospital stay duration in COVID-19 patients. This retrospective study analyzed epidemiological data, comorbidities, metabolic/inflammatory markers, and clinical information from 165 SARS-CoV-2 positive patients. In a multiple linear regression model, an IL-6 higher than 100 mg/L, glucose at admission (baseline levels at the hospital entry), and the interaction between ACEI administration and LDH predicted the days of hospital admission (P < 0.001). In conclusion, hypertensive patients suffering more severe inflammatory condition assessed by LDH levels clinically benefited more and reduced the hospital stay when prescribed ACEI agents than those with lower systemic baseline inflammation at admission. Elsevier Inc. 2022-04 2022-01-20 /pmc/articles/PMC8769875/ /pubmed/35065299 http://dx.doi.org/10.1016/j.vph.2022.106955 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Martínez-Urbistondo, Maria Moreno-Torres, Víctor Mora-Vargas, Alberto Expósito-Palomo, Esther Castejón-Díaz, Raquel Daimiel, Lidia Ramos-Lopez, Omar San-Cristóbal, Rodrigo Vargas, Juan A. Martínez, J. Alfredo Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title | Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title_full | Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title_fullStr | Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title_full_unstemmed | Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title_short | Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes |
title_sort | interaction of acei antihypertensive agent's administration with the inflammatory status at admission concerning covid-19 clinical stay outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769875/ https://www.ncbi.nlm.nih.gov/pubmed/35065299 http://dx.doi.org/10.1016/j.vph.2022.106955 |
work_keys_str_mv | AT martinezurbistondomaria interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT morenotorresvictor interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT moravargasalberto interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT expositopalomoesther interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT castejondiazraquel interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT daimiellidia interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT ramoslopezomar interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT sancristobalrodrigo interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT vargasjuana interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes AT martinezjalfredo interactionofaceiantihypertensiveagentsadministrationwiththeinflammatorystatusatadmissionconcerningcovid19clinicalstayoutcomes |